These new drugs have been reported to significantly improve the overall survival (OS), progression‐free survival (PFS), and objective response rate (ORR) in advanced NSCLC patients who are EGFR gene mutation positive, ALK gene mutation positive, or PD‐L1 expression positive. This evidence concerns the gene EGFR and non-small cell lung carcinoma.